Navigation Links
BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference

rances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trial for Fodosine(TM) that is currently planned to be pivotal, that we may not be able to commence the proposed Phase III trial for peramivir within the time frame we currently expect or at all, that we may not be able to announce preclinical developments for additional compounds by year-end 2007 as currently proposed, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

CONTACT: Jonathan M. Nugent, V.P. Corporate Communications of BioCrystPharmaceuticals, Inc., +1-205-444-4633, jnugent@biocryst.com

Web site: http://www.biocryst.com/

Ticker Symbol: (NASDAQ-NMS:BCRX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
(Date:8/29/2014)... August 29, 2014 According ... Product & Services (Equipment, Reagent, Primer, Probe, Custom ... PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - ... global Oligonucleotide Synthesis Market is expected to reach ... 2014, growing at a CAGR of 9.8% from ...
(Date:8/29/2014)... 29, 2014  In part four of ... hospital pharmacy as a strategic asset, Mary Baxter, ... for Cardinal Health,s Innovation Delivery Solutions business, discusses how ... both hospitals and patients. "Every hospital pharmacist ... of their job in a value-based healthcare world," Baxter ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition ... Market 2014-2018" report to their offering. ... that connect, support, or surround bones. There are several ... cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, ... result in wear and tear in these tissues. Orthopedic ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... Phosphagenics,Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today ... undertake a Phase 1 transdermal,oxycodone clinical trial aimed ... management product. Phosphagenics has submitted all necessary ... be conducted at CMAX - an independent clinical ...
... Phase 2 clinical development, PRINCETON, N.J., Sept. ... in the discovery and development of novel,small molecule ... 2a,clinical study of PS433540, the company,s lead internal ... receptor antagonist,(DARA) that is being developed as a ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
(Date:8/30/2014)... Skmen.com, a well-known clothing manufacturer, has announced its promotion ... middle of September, all the company’s new and old ... 30 percent off. , As a matter of ... made and come with quality guarantees. They can certainly ... popular for its fashionable, high quality clothes for men ...
(Date:8/30/2014)... TX (PRWEB) August 30, 2014 Information ... Pros company to introduce better prices to consumers in ... plans can be found when using the open system ... national lookup system available to use this year can ... insurance based on general location and not from medical ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 ... a Spa-on-Wheels which offers the complete spa experience ... inviting lighting and the most important ingredient of ... "the dedicated licensed pro's! People will enjoy the ... continues Kaplan-Pelle. The website reads, "Step into the ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 Daily ... Carter, called the Make Him Desire You program, who shows ... heart. , The author of this method says that the ... guys. , The Make Him Desire You review indicates that ... reveals amazing insider advice and his great techniques to make ...
(Date:8/30/2014)... August 30, 2014 Daily Gossip reveals in ... Infection is a method created by Sarah Summer, who can ... The author of this new program actually had to deal ... sufferer to be able to access it, in an all-natural ... determination in finding an effective cure for yeast infection. The ...
Breaking Medicine News(10 mins):Health News:Huge Deals On 2014 Long Casual Dresses Unveiled By Skmen.com 2Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2
... Celator Pharmaceuticals today announced that new data ... in consolidation treatment for leukemia and of CPX-1 ... agents for the treatment of colorectal cancer were ... American Association for Cancer Research (AACR) in Denver, ...
... REDWOOD CITY, Calif., April 22 AcelRx Pharmaceuticals, ... Phase 2 clinical trial of ARX-02, a proprietary ... pain control. The primary objective of this multicenter, ... tolerability and efficacy of ARX-02 relative to placebo ...
... OAK BROOK, Ill., April 22 The ... of Minnesota have agreed to conditions for ... receive certain services from DeCare Dental following ... certain business functions that DeCare previously performed ...
... on the list. , ... Newport Beach, CA (Vocus) April 22, 2009 ... of four hospitals in Los Angeles and Orange Counties and one of ... as reported by AARP The Magazine. The designation of a "top hospital" ...
... is committed to providing people with skin care ... practical advice and helpful insights are provided by ... devotion to cosmetic dermatology. The content is written ... wide range of practical advice. Key portions of ...
... its commitment to seniors on Medicaid. New Jersey ... Assisted Living Concepts, revealed a history of evictions when ... , WESTBURY, N.Y., April 22 Raphael Weiss, Managing ... ( www.AmberCourtAL.com ), assured that his ...
Cached Medicine News:Health News:Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research 2Health News:Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research 3Health News:AcelRx Announces Initiation of Phase 2 Cancer Breakthrough Pain Program 2Health News:Delta Dental Plans Association and Delta Dental of Minnesota Agree to Conditions Regarding Supplier 2Health News:Hoag named in top 125 hospitals by Consumers' CHECKBOOK as reported by AARP The Magazine 2Health News:Beauty-Doctors Website Provides Dermatologist-Authored Skin Care Information from Experts 2Health News:Amber Court Assisted Living Communities Reaffirms its Commitment to Seniors on Medicaid 2
... A biopsy with the MAMMOTOME® ... effective, minimally invasive procedure using ... management.,Using computer-generated images to locate ... accurately pinpoint and map the ...
... SEAMGUARD® Staple Line Reinforcement Material is ... postoperative pulmonary air leaks and as ... This inert, biocompatible, ePTFE material requires ... easy to load and fire and ...
... for the repair of abdominal hernias. It ... two distinct sides. One side of ... of sodium hyaluronate and carboxymethylcellulose (similar to ... side is bioresorbable, providing a temporary physical ...
... The Hernia Repair Company, we recognize that ... limited fibrous tissue in-growth between the prosthesis ... polypropylene mesh. Like all the products in ... produces a clinically proven, versatile repair.,The Reconix ...
Medicine Products: